Clinical guidelines for overactive bladder: Guidelines

International Journal of Urology

Volumn 16, Issue 2, 2009, Pages 126-142

  Yamaguchi, Osamu ^a   Nishizawa, Osamu ^b   Takeda, Masayuki ^c   Yokoyama, Osamu ^d   Homma, Yukio ^e   Kakizaki, Hidehiro ^f   Obara, Kenji ^g   Gotoh, Momokazu ^h   Igawa, Yasuhiko ^b   Seki, Naarihito ⁱ   Yoshida, Masaki ^j  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d UNIVERSITY OF FUKUI   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f ASAHIKAWA MEDICAL COLLEGE   (Japan)

^g NIIGATA UNIVERSITY   (Japan)

^h NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

^j KUMAMOTO UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMITRIPTYLINE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BOTULINUM TOXIN; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; DARIFENACIN; FLAVOXATE; IMIDAFENACIN; IMIPRAMINE; KUC 7483; OXYBUTYNIN; PLACEBO; POTASSIUM CHANNEL STIMULATING AGENT; PROPANTHELINE BROMIDE; PROPIVERINE; RESINIFERATOXIN; SOLIFENACIN; TACHYKININ; TAMSULOSIN; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; YM 178; ZD 094;

ABSENCE OF SIDE EFFECTS; ACCOMMODATION DISORDER; ALGORITHM; BEHAVIOR THERAPY; CHILD REARING; CLINICAL EVALUATION; CLINICAL TRIAL; CONSTIPATION; DETRUSOR MUSCLE; DIAGNOSTIC ACCURACY; DRUG DOSAGE FORM; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROSTIMULATION; EXERCISE; GROUPS BY AGE; HEART VENTRICLE ARRHYTHMIA; HUMAN; LIFESTYLE MODIFICATION; MAGNETIC STIMULATION; MICTURITION DISORDER; MONOTHERAPY; NEUROMODULATION; NOCTURIA; ORTHOSTATIC HYPERTENSION; OVERACTIVE BLADDER; OVERACTIVE BLADDER SYMPTOM SCORE; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; SEX DIFFERENCE; SIDE EFFECT; SYMPTOM; UNSPECIFIED SIDE EFFECT; URINARY URGENCY; URINE INCONTINENCE; XEROSTOMIA;

ANTI-DYSKINESIA AGENTS; ANTIDEPRESSIVE AGENTS; BEHAVIOR CONTROL; BOTULINUM TOXINS; CAPSAICIN; CHOLINERGIC ANTAGONISTS; DITERPENES; FLAVOXATE; HUMANS; PARASYMPATHOLYTICS; PHYSICAL THERAPY MODALITIES; SENSORY SYSTEM AGENTS; URINARY BLADDER, OVERACTIVE;

EID: 60349131528     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02177.x     Document Type: Review

References (129)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence society. Neurourol. Urodyn. 2002 21 : 167 78.
2. Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: Do we need urodynamics? Neurourol. Urodyn. 2003 22 : 105 8.
3. Flisser AJ, Walmsley K, Blaivas JG. Urodynamic classification of patients with symptoms of overactive bladder. J. Urol. 2003 169 : 529 34.
4. van Brummen HJ, Heintz APM, van der Vaart CH. The association between overactive bladder symptoms and objective parameters from bladder diary and filling cystometry. Neurourol. Urodyn. 2004 23 : 38 42.
5. Homma Y, Kakizaki H, Gotoh M, Takei M, Yamanishi T, Hayashi K. Epidemiological Research Committee on Micturition. Epidemiologic survey on urination in Japan. J. Neurogenic Bladder Soc. 2003 14 : 266 77.
6. Homma Y, Ando T, Yoshida M et al. Preparation of a questionnaire for urinary incontinence symptoms (1st report): Presentation of questionnaire. J. Neurogenic Bladder Soc. 2003 14 : 240 7.
7. Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, Abrams P. The Bristol Female Lower Urinary Tract Symptoms questionnaire : Development and psychometric testing. Br. J. Urol. 1996 77 : 805 12.
8. Donovan JL, Abrams P, Peters TJ et al. The ICS-'BPH' Study: The psychometric validity and reliability of the ICS male questionnaire. Br. J. Urol. 1996 77 : 554 62.
9. Barry MJ, Fowler FJ Jr., O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol. 1992 148 : 1549 57.
10. O'Leary MP, Sant GR, Fowler FJ Jr., Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology 1997 49 (Suppl 5 58 63.
11. Bower WF, Moore KH, Adams RD. A novel clinical evaluation of childhood incontinence and urinary urgency. J. Urol. 2001 166 : 2411 15.
12. Homma Y, Paick JS, Lee JG, Kawabe K. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: A randomized, placebo-controlled trial. BJU Int. 2003 92 : 741 7.
13. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: Systematic review. BMJ 2003 326 : 841 4.
14. Freeman R, Hill S, Millard R, Slack M, Sutherst J. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet. Gynecol. 2003 102 : 605 11.
15. Homma Y, Ando T, Yoshida M et al. Voiding and incontinence frequencies: Variability of diary data and required diary length. Neurourol. Urodyn. 2002 21 : 204 9.
16. Schick E, Jolivet-Tremblay M, Dupont C, Bertrand PE, Tessier J. Frequency-volume chart: The minimum number of days required to obtain reliable results. Neurourol. Urodyn. 2003 22 : 92 6.
17. Brown JS, McNaughton KS, Wyman JF et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology 2003 61 : 802 9.
18. Ku JH, Jeong IG, Lim DJ, Byun SS, Paick JS, Oh SJ. Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms: Prospective assessment of patient compliance and burden. Neurourol. Urodyn. 2004 23 : 331 5.
19. Homma Y, Yoshida M, Obara K, Seki N, Yamaguchi O. Development and validity of the Overactive Bladder Symptom Score (OABSS). Jpn J. Urol. 2005 96 : 182.
20. Homma Y, Matsui K, Yamaguchi O. Lower limits for overactive bladder. J. Neurogenic Bladder Soc. 2004 15 : 109.
21. Dowd TT, Campbell JM, Jones JA. Fluid intake and urinary incontinence in older community-dwelling women. J. Community Health Nurs. 1996 13 : 179 86 (Level IV).
22. Bryant CM, Dowell CJ, Fairbrother G. A randomised trial of the effects of caffeine upon frequency, urgency and urge incontinence. Neurourol. Urodyn. 2000 19 : 501 2 (Level II).
23. Jarvis GJ, Millar DR. Controlled trial of bladder drill for detrusor instability. BMJ 1980 281 : 1322 23 (Level II).
24. Fantl JA, Wyman JF, McClish DK et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991 265 : 609 13 (Level II).
25. Wyman JF, Fantl JA, McClish DK, Bump RC. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. Am. J. Obstet. Gynecol. 1998 179 : 999 1007 (Level I).
26. Jarvis GJ. A controlled trial of bladder drill and drug therapy in the management of detrusor instability. Br. J. Urol. 1981 53 : 565 6 (Level II).
27. Colombo M, Zanetta G, Scalambrino S, Milani R. Oxybutynin and bladder training in the management of female urinary urge incontinence: A randomized study. Int. Urogynecol. J. 1995 6 : 63 7 (Level II).
28. Goode PS, Burgio KL, Locher JL, Umlauf MG, Lloyd LK, Roth DL. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J. Am. Geriatr. Soc. 2002 50 : 808 16 (Level I).
29. Burns PA, Pranikoff K, Nochajski TH, Hadley EC, Levy KJ, Ory MG. A comparison of effectiveness of biofeedback and pelvic muscle exercise treatment of stress incontinence in older community-dwelling women. J. Gerontol. 1993 48 : M167 74 (Level II).
30. Nygaard IE, Kreder KJ, Lepic MM, Fountain KA, Rhomberg AT. Efficacy of pelvic floor muscle exercises in women with stress, urge and mixed urinary incontinence. Am. J. Obstet. Gynecol. 1996 174 : 120 5 (Level II).
31. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J. Am. Geriatr. Soc. 2000 48 : 370 4 (Level I).
32. Burgio KL, Goode PS, Locher JL et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: A randomized controlled trial. JAMA 2002 288 : 2293 99 (Level I).
33. Colling J, Ouslander J, Hadley BJ, Eisch J, Campbell E. The effects of patterned urge-response toileting (PURT) on urinary incontinence among nursing home residents. J. Am. Geriatr. Soc. 1992 40 : 135 41 (Level I).
34. Thüroff JW, Chartier-Kastler E, Corcus J et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J. Urol. 1998 16 (Suppl 1 S48 61 (Review).
35. Amarenco G, Marquis P, McCathy C, Richard F. Quality of life of women with stress urinary incontinence with or without pollakiuria Presse Med. 1998 27 : 5 10 (in French) (Level I).
36. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J. Clin. Pharmacol. 2001 41 : 636 44 (Level II).
37. Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride. J. Am. Geriatr. Soc. 1998 46 : 8 13 (Level II).
38. Ouslander JG, Shih YT, Malone-Lee J, Luber K. Overactive bladder: Special considerations in the geriatric population. Am. J. Manag. Care 2000 11 (Suppl 6 S599 606 (Review).
39. Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet. Gynecol. 2000 95 : 718 21 (Level I).
40. Appell RA, Sand P, Dmochowski R et al. Judging Effective Control and Treatment Study Group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT Study. Mayo Clin. Proc. 2001 76 : 358 63 (Level I).
41. Enzelsberger H, Helmer H, Kurz C. Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: A randomised trial. Br. J. Obstet. Gynaecol. 1995 102 : 929 30 (Level II).
42. Kaplinsky R, Greenfield S, Wan J, Fera M. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder. J. Urol. 1996 156 : 753 6 (Level IV).
43. Winkler HA, Sand PK. Treatment of detrusor instability with oxybutynin rectal suppositories. Int. Urogynecol. J. Pelvic Foor Dysfunct. 1998 9 : 100 2 (Level IV).
44. Dmochowski RR, Davila GW, Zinner NR et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J. Urol. 2002 168 : 580 6 (Level I).
45. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003 62 : 237 42 (Level I).
46. Stohrer M, Madersbacher H, Richter R, Wehnert J, Dreikorn K. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia: A double-blind, placebo-controlled clinical trial. Spinal Cord. 1999 37 : 196 200 (Level I).
47. Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int. 1999 84 : 646 51 (Level I).
48. Dorschner W, Stolzenburg JU, Griebenow R et al. Efficacy and cardiac safety of propiverine in elderly patients: A double-blind, placebo-controlled clinical study. Eur. Urol. 2000 37 : 702 8 (Level I).
49. Homma Y, Paick JS, Lee JG, Kawabe K. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: A randomized, placebo-controlled trial. BJU Int. 2003 92 : 741 7 (Level I).
50. Takei M, Homma Y. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Int. J. Urol. 2005 12 : 456 64 (Level V).
51. Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am. J. Manag. Care 2002 8 (Suppl S608 615 (Level I).
52. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The antimuscarinic clinical effectiveness trial (ACET). Curr. Med. Res. Opin. 2002 18 : 177 84 (Level I).
53. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J. Am. Geriatr. Soc. 2002 50 : 799 807 (Level I).
54. Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: The IMPACT trial. Int. J. Clin. Pract. 2006 60 : 745 51 (Level V).
55. Roberts R, Bavendam T, Glasser DB, Carlsson M, Eyland N, Elinoff V. Tolterodine extended release improves patient-reported outcomes in overactive bladder: Results from the IMPACT trial. Int. J. Clin. Pract. 2006 60 : 752 8 (Level V).
56. Dmochowski R, Kreder K, MacDiarmid S, Carlsson M, Guan Z. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. BJU Int. 2007 100 : 107 10 (Level I).
57. Landis JR, Kaplan S, Swift S, Versi E. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J. Urol. 2004 171 : 752 6 (Level V).
58. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an [alpha]-blocker plus an anticholinergic for bladder outlet obstruction: A prospective, randomized, controlled study. J. Urol. 2003 169 : 2253 6 (Level II).
59. Yamaguchi O, Marui E, Kakizaki H et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007 100 : 579 87 (Level I).
60. Yamaguchi O. Long-term safety and efficacy of solifenacin succinate in patients with overactive bladder. Jpn Pharmacol Ther. 2006 34 : S69 86 (Level V).
61. Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur. Urol. 2005 48 : 464 70 (Level I).
62. Chapple CR, Fianu-Jonsson A, Indig M et al. Treatment outcomes in the STAR study: A subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur. Urol. 2007 52 : 1195 203 (Level I).
63. Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J. Urol. 2004 172 : 1919 24 (Level I).
64. Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int. J. Clin. Pract. 2006 60 : 959 66 (Level I).
65. Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 2005 95 : 81 5 (Level I).
66. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. Am. J. Geriatr. Pharmacother. 2006 4 : 14 24 (Level I).
67. Millard RJ, Halaska M. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: A pooled analysis. Curr. Med. Res. Opin. 2006 22 : 41 8 (Level I).
68. Cardozo L, Castro-Diaz D, Gittelman M, Ridder A, Huang M. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int. Urogynecol. J. 2006 17 : 512 19 (Level I).
69. Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: A pooled analysis. Eur. Urol. 2005 48 : 483 7 (Level I).
70. Brubaker L, FitzGerald MP. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int. Urogynecol. J. 2007 18 : 737 41 (Level I).
71. Haab F, Cardozo L, Chapple C, Ridder AM. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur. Urol. 2005 47 : 376 84 (Level III).
72. Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: The VESIcare Open-Label Trial (VOLT). Clin. Ther. 2006 28 : 1935 46 (Level V).
73. Garely AD, Lucente V, Vapnek J, Smith N. Solifenacin for overactive bladder with incontinence: Symptom bother and health-related quality of life outcomes. Ann. Pharmacother. 2007 41 : 391 9 (Level V).
74. Michel MC, Wetterauer U, Vogel M, de la Rosette JJMCH. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use. Drug Saf. 2008 31 : 505 14 (Level V).
75. Cardozo L, Nagy G, Kiss L et al. Solifenacin in the treatment of urgency symptoms of overactive bladder in a flexible dose, placebo controlled trial (the SUNRISE study). Int. Urogynecol. J. 2006 17 (Suppl 2 S88 9 (Abstr 052) (Level I).
76. Serels S, Andoh M, Smith N. Solifenacin significantly improves urgency in overactive bladder (OAB) patients compared to placebo. Urology 2006 68 (Suppl 5A 72 (Abstr MP-04.11) (Level I).
77. Toglia M, Andoh M, Hussain I. Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder. Neurourol. Urodyn. 2006 655 : 25 (Abstr 123) (Level I).
78. Thüroff JW, Bunke B, Ebner A et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: Oxybutynin versus propantheline versus placebo. J. Urol. 1991 145 : 813 16 (Level I).
79. Holmes DM, Montz FJ, Stanton SL. Oxybutinin versus propantheline in the management of detrusor instability. A patient-regulated variable dose trial. Br. J. Obstet. Gynaecol. 1989 96 : 607 12 (Level II).
80. Ruffmann R. A review of flavoxate hydrochloride in the treatment of urge incontinence. J. Int. Med. Res. 1988 16 : 317 30 (Level IV).
81. Chapple CR, Parkhouse H, Gardener C, Milroy EJ. Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability. Br. J. Urol. 1990 66 : 491 4 (Level III).
82. Milani R, Scalambrino S, Milia R et al. Double-blind crossover comparison of flavoxate and oxybutynin in women affected by urinary urge syndrome. Int. Urogynecol. J. 1993 4 : 3 8 (Level III).
83. Castleden CM, Duffin HM, Gulati RS. Double-blind study of imipramine and placebo for incontinence due to bladder instability. Age Ageing 1986 15 : 299 303 (Level II).
84. Raezer DM, Benson GS, Wein AJ, Duckett JW Jr. The functional approach to the management of the pediatric neuropathic bladder: A clinical study. J. Urol. 1977 117 : 649 54 (Level V).
85. Hunsballe JM, Djurhuus JC. Clinical options for imipramine in the management of urinary incontinence. Urol. Res. 2001 29 : 118 25 (Review).
86. Cruz F. Vanilloid receptor and detrusor instability. Urology 2002 59 (Suppl 5 51 60 (Review).
87. de Groat WC, Kawatani M, Hisamitsu T et al. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J. Auton. Nerv. Syst. 1990 30 (Suppl S71 7 (Review).
88. Fowler CJ, Jewkes D, McDonald WI, Lynn B, de Groat WC. Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992 339 : 1239 (Level IV).
89. de Sèze M, Wiart L, Joseph PA, Dosque JP, Mazaux JM, Barat M. Capsaicin and neurogenic detrusor hyperreflexia: A double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol. Urodyn. 1998 17 : 513 23 (Level II).
90. Cruz F, Guimaraes M, Silva C, Reis M. Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet 1997 350 : 640 1 (Level IV).
91. Silva C, Rio ME, Cruz F. Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: Long-term results for the treatment of detrusor hyperreflexia. Eur. Urol. 2000 38 : 444 52 (Level IV).
92. Silva C, Ribeiro MJ, Cruz F. The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J. Urol. 2002 168 : 575 9 (Level IV).
93. Kuo HC. Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions. J. Urol. 2003 170 : 835 9 (Level IV).
94. Giannantoni A, Di Stasi SM, Stephen RL et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J. Uro1. 2002 167 : 1710 14 (Level III).
95. de Sèze M, Wiart L, de Sèze MP et al. Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: A double-blind, randomized, controlled study. J. Urol. 2004 171 : 251 5 (Level II).
96. Yokoyama T, Nozaki K, Fujita O, Nose H, Inoue M, Kumon H. Role of C afferent fibers and monitoring of intravesical resiniferatoxin therapy for patients with idiopathic detrusor overactivity. J. Urol. 2004 172 : 596 600 (Level III).
97. de Sèze M, Petit H, Gallien P et al. Botulinum A toxin and detrusor sphincter dyssynergia: A double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur. Urol. 2002 42 : 56 62 (Level V).
98. Reitz A, von Tobel J, Stöhrer M et al. European experience of 184 cases treated with botulinum-A toxin injections into the detrusor muscle for neurogenic incontinence. Neurourol. Urodyn. 2002 21 : 427 8 (Level V).
99. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: A prospective randomized study. J. Urol. 2004 172 : 240 3 (Level II).
100. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur. Urol. 2004 45 : 420 9 (Level I).
101. Tršinar B, Kraij B. Maximal electrical stimulation in children with unstable bladder and nocturnal enuresis and/or daytime incontinence: A controlled study. Neurourol. Urodyn. 1996 15 : 133 42 (Level I).
102. Abel I, Ottesen B, Fischer-Rasmussen W, Lose G. Maximal electrical stimulation of the pelvic floor in the treatment of urge incontinence: A placebo-controlled study. Neurourol. Urodyn. 1996 15 : 283 4 (Level II).
103. Bower WF, Moore KH, Adams RD. Randomised sham-controlled trial of two surface neuromodulation sites in women with detrusor instability. Neurourol. Urodyn. 1997 16 : 428 9 (Level II).
104. Yamanishi T, Yasuda K, Sakakibara R, Hattori T, Suda S. Randomized, double-blind study of electrical stimulation for urinary incontinence due to detrusor overactivity. Urology 2000 55 : 353 7 (Level II).
105. Yasuda K, Kawabe K, Sato A et al. Double-blind crossover study of the TEU-20 interference low-frequency device for urinary frequency, urgency, and incontinence. Jpn J. Urol. Surg. 1994 7 : 297 324 (Level II).
106. Suzuki S, Kawabe K, Kageyama S et al. Long-term clinical use of the TEU-20 interference low-frequency device for urinary frequency, urgency, and incontinence. Jpn J. Urol. Surg. 1994 7 : 529 40 (Level V).
107. Fujishiro T, Takahashi S, Enomoto H, Ugawa Y, Ueno S, Kitamura T. Magnetic stimulation of the sacral roots for the treatment of urinary frequency and urge incontinence: An investigational study and placebo controlled trial. J. Urol. 2002 168 : 1036 9 (Level II).
108. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: Correlation of lower urinary tract symptoms with urodynamic findings. J. Urol. 2001 166 : 550 3 (Level III).
109. Abrams P, Cardozo L, Fall M et al. The Standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 2002 21 : 167 78 (Level V).
110. Abram P. Detrusor instability and bladder outlet obstruction. Neurourol. Urodyn. 1985 4 : 317 28 (Level III).
111. Bates CP, Whiteside CG, Turner-Warwick R. Synchronous cine/pressure/flow/cysto/urethrography with special reference to stress and urge incontinence. Br. J. Urol. 1970 42 : 714 23 (Level IV).
112. van Waalwijk van Doorn E, Anders K, Khullar V et al. Standardisation of ambulatory urodynamic monitoring: Report of the Standardisation Sub-committee of the International Continence Society for Ambulatory Urodynamic Studies. Neurourol. Urodyn. 2000 19 : 113 25 (Level V).
113. Wein AJ. Overactive bladder: Defining the disease. Am. J. Manag. Care 2000 6 (11 Suppl S559 64 (Level V).
114. Research Group on the Standardization of Urological Treatment (ed.) EBM-based Guidelines for the Treatment of Benign Prostatic Hyperplasia. Tokyo : Jiho, 2001 (Level V).
115. Gormley EA, Griffiths DJ, McCracken PN, Harrison GM, McPhee MS. Effect of transurethral resection of the prostate on detrusor instability and urge incontinence in elderly males. Neurourol. Urodyn. 1993 12 : 445 53 (Level V).
116. Nitti VW, Kim Y, Combs AJ. Voiding dysfunction following transurethral resection of the prostate: Symptoms and urodynamic findings. J. Urol. 1997 157 : 600 3 (Level V).
117. Thomas AW, Cannon A, Barlett E, Ellis-Jones J, Abrams P. The long term urodynamic follow-up of TURP: A study of the prevalence of detrusor instability. J. Urol. 1999 161 (Suppl 257 (Level V).
118. Bosch JL. Urodynamic effects of various treatment modalities for benign prostatic hyperplasia. J. Urol. 1997 158 : 2034 44 (Level V).
119. Van Venrooij GE, Van Melick HH, Eckhardt MD, Boon TA. Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J. Urol. 2002 168 : 605 9 (Level IV).
120. Dmochowski RR, Staskin D. Overactive bladder in men: Special considerations for evaluation and management. Urology 2002 60 (Suppl 5 56 62 (Level IV).
121. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. 1999 36 : 1 13 (Level I).
122. Witjes WP, Rosier PF, Caris CT, Debruyne FM, de la Rosette JJ. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: A stratified analysis. Urology 1997 49 : 197 206 (Level I).
123. Gerber GS, Kim JH, Contreras BA, Steinberg GD, Rukstalis DB. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Urology 1996 47 : 840 4 (Level IV).
124. Gerber GS, Contreras BA, Zagaja GP, Kim JH, Steinberg GD, Rukstalis DB. Doxazosin in men with lower urinary tract symptoms: Urodynamic evaluation at 15 months. Urology 1997 50 : 229 33 (Level IV).
125. Abrams P. Tolterodine therapy in men with bladder outlet obstruction and symptomatic detrusor overactivity is not associated with urinary safety concerns. J. Urol. 2002 167 (Suppl 266 (Level IV).
126. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: A prospective, randomized, controlled study. J. Urol. 2003 169 : 2253 6 (Level II).
127. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial. JAMA 2006 296 : 2319 28 (Level I).
128. Brubaker L. Electrical stimulation in overactive bladder. Urology 2000 55 (Suppl 5 17 23 (Level V).
129. Yamanishi T, Sakakibara R, Uchiyama T et al. Comparative study of the effects of magnetic versus electrical stimulation on inhibition of detrusor overactivity. Urology 2000 56 : 777 81 (Level II).